x

Posted 16 May, 2023

SERA PROGNOSTICS, INC. appointed Dr. Critchfield as new CEO

Nasdaq:SERA appointed new Chief Executive Officer Dr. Critchfield in a 8-K filed on 16 May, 2023.


  Concurrently with Dr. Critchfield's retirement, Zhenya Lindgardt, a member of the Board, was appointed as the Interim Chief Executive Officer of the Company, effective June 8, 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of SERA PROGNOSTICS, INC.
Health Care/Life Sciences • Biotechnology
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.
Market Cap
$147M
View Company Details
SERA PROGNOSTICS, INC. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 14, 2023, Gregory C. Critchfield, M.D., M.S. notified Sera Prognostics, Inc. (the "Company") of his intention to retire from the position of President and Chief Executive Officer of the Company and Chairman of the Board of Directors (the "Board"), effective as of June 8, 2023 (the "Retirement Date"). Kim Kamdar, Ph.D., a member of the Board, has been appointed as Chairperson of the Board, effective as of the Retirement Date. Dr. Critchfield currently intends to continue his service as a member of the Board. 

In connection with Dr. Critchfield's retirement from his executive position with the Company, the Company has entered into a transition agreement with Dr. Critchfield. The terms of such agreement will be summarized in a subsequent Current Report on Form 8-K.

Concurrently with Dr. Critchfield's retirement, Zhenya Lindgardt, a member of the Board, was appointed as the Interim Chief Executive Officer of the Company, effective June 8, 2023. Ms. Lindgardt's biographical information can be found under the caption "Board of Directors and Corporate Governance" in the Company's Definitive Proxy Statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on April 25, 2023, and such biographical information is incorporated herein by reference. Biographical information about Ms. Lindgardt can also be found on the Company's website.

There is no arrangement or understanding with any person pursuant to which Ms. Lindgardt was appointed as the Interim Chief Executive Officer of the Company. There are no family relationships between Ms. Lindgardt and any director or executive officer of the Company, and she is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K.

The Company anticipates entering into an employment agreement with Ms. Lindgardt, the material terms of which will be disclosed in a Current Report on Form 8-K when the agreement is finalized.